What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.

What especially shook investors was the prospect that China may have closed the tech gap with the United States in AI and especially DeepSeek’s claim that it developed R1 for just $5.6 million—a far ...

This summary highlights significant health news, covering topics such as HIV treatment during U.S. aid pauses, Pfizer's diversity program legal settlement, AstraZeneca's halted UK investment, data ...

Researchers from across the country believe they have developed a breakthrough weight loss drug treatment: two new peptide ...

Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. The strong market debut of ...

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...

Aneesa Ferreira is getting fit! The Challenge star posted a new before-and-after look at her recent weight loss over the past ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...